Eli Lilly and Co at Sanford C Bernstein Operational Decisions Conference (Virtual) Transcript

Nov 16, 2020 / 04:00PM GMT
Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst

Hi, everybody, and thank you for joining us today. In this session of the ODC, we have a special treat for you. Kevin and the Eli Lilly IR team were kind enough to let us have a conversation today with 3 of their scientific leader: Andrew Adams, who runs the new therapeutic area modalities and also the COVID-19 section; Mark Mintun, I hope I'm not ruining your name too much, the VP of neurodegeneration and pain and himself quite a notable neurodegeneration scientist; and Jeff Emmick, who is the VP of diabetes products development, in charge on, I guess, all the clinical side of diabetes products and a few other related areas.

So what we've designed is probably a bit of a too long of a conversation with each one of them for the next 45 minutes. I'll try to kind of stay 15 minutes per topic. The first discussion will be around COVID, then neurodegeneration and diabetes will close us up.

Questions and Answers:

Aaron Gal - Sanford C. Bernstein & Co., LLC., Research
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot